Taken together, these data imply that Hes1 on TAMs promotes tumor growth in a way that limits the activities of CD4+ and CD8+ T cells and represents a promising therapeutic approach, especially when combined with existing anti-tumor therapies. Here, CD4 is linked to neoplasm.